September 17, 2013

European Commission Approves Genzyme’s Multiple Sclerosis Treatment LemtradaTM (alemtuzumab)

Follows Recent European Commission Approval of Multiple Sclerosis Treatment Aubagio® (teriflunomide)

Approvals Set the Stage for Launches Throughout EU and Strongly Position Genzyme as a Committed Partner to the MS Community

 

European Commission Approves Genzyme’s Multiple Sclerosis Treatment LemtradaTM (alemtuzumab)
Follows Recent European Commission Approval of Multiple Sclerosis Treatment Aubagio® (teriflunomide)

Content